2023 Annual Meeting | C194 - Alzheimer's Disease

Date Thursday 04/27/23

Time 01:00 PM - 03:00 PM EST Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Liliana A. Ramirez-Gomez, MD, FAAN

Topic(s) Aging, Dementia, and Behavioral Neurology

Learning Objectives Participants will be introduced to the concept of AD as a clinicopathologic entity and explain approaches to detect AD early in the disease continuum; discuss the range of biomarker breakthroughs to detect AD, including blood base, CSF, and neuroimaging biomarkers, and the role of these tools in research and clinical practice; discuss the importance of integrating clinical assessment and biomarkers to obtain an early diagnosis; recognize and understand the clinical heterogeneity in AD; discuss the most recent therapeutic advances and emerging therapies for Alzheimer's disease; and discuss the Appropriate Use Recommendations for monoclonal antibodies. Considerations on how to achieve equity in dementia care and research will also be discussed.

This program is supported in part by an educational grant from Eisai, Inc.

The Academy was solely responsible, with no influence from the industry supporter, for selection of content, format, presenters, and moderators of this CME program, and the speakers have not been contacted or influenced in any way by the industry supporter with regard to this CME program.

CME Available 2.00 CME credits

Core Competencies Patient Care & Procedural Skills, Medical Knowledge

Program Level Introductory

Program Tracks Diversity, Equity, and Inclusion, Advanced Practice Provider

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Advanced Practice Provider

Teaching Styles Didactic, Audience Participation

Event Timeline
01:00 PM - 01:05 PM EST	Introduction	Welcome and Introductions Liliana A. Ramirez-Gomez, MD, FAAN
01:05 PM - 01:40 PM EST	Speaker	Diagnosis of Alzheimer's Disease in the Era of In Vivo Biomarkers Jasmeer Chhatwal, MD, PhD
01:40 PM - 02:15 PM EST	Speaker	Monoclonal Antibodies for the Treatment of Alzheimer's Disease Jeremy J. Pruzin, MD
02:15 PM - 02:45 PM EST	Speaker	Towards Achieving Equity in Dementia Care and Research Liliana A. Ramirez-Gomez, MD, FAAN
02:45 PM - 03:00 PM EST	Discussion	Questions and Answers Liliana A. Ramirez-Gomez, MD, FAAN, Jasmeer Chhatwal, MD, PhD, Jeremy J. Pruzin, MD

Faculty Disclosures
Jasmeer Chhatwal, MD, PhD	Dr. Chhatwal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for ExpertConnect. Dr. Chhatwal has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Humana Healthcare.
Liliana A. Ramirez-Gomez, MD, FAAN	The institution of Dr. Ramirez-Gomez has received research support from NIA-NIH.
Jeremy J. Pruzin, MD	Dr. Pruzin has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Eisai. Dr. Pruzin has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedNet. Dr. Pruzin has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Synapticure. The institution of Dr. Pruzin has received research support from NIA.

��ɫ��

��ɫ��